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Abstract—A series of N-aryl isonipecotamide α-sulfone hydroxamate derivatives has been 
prepared utilizing a combination of solution-phase and resin-bound library technologies to afford 
compounds that are potent and highly selective for MMP-13. 
 
Matrix metalloproteinases (MMPs) are zinc-dependent enzymes that are responsible for 
remodeling and degradation of all components of the extracellular matrix,1,2 yet excessive 
activity of MMPs has been implicated in numerous disease states including cancer,3,4 arthritis5 
and cardiovascular disease.6-9  MMP inhibitors (MMPi's) have therefore been explored as 
therapeutic treatments to halt progression of various diseases.10-12  The MMP family of enzymes 
includes at least 24 distinct mammalian isozymes, but MMP-13 in particular has been identified 
as a significant target since its upregulation has been implicated in cancer,  osteoarthritis and 
cardiovascular disease.   
 
Treatment of patients with broad-spectrum MMPi’s gives rise to stiffening of the joints 
referred to as musculoskeletal syndrome9 (MSS).  Inhibition of MMP-1 has been hypothesized to 
be the cause of MSS observed clinically with broad-spectrum inhibitors, and the broad-spectrum 
inhibitor marimastat induces musculoskeletal side effects in rats.13   MMP-1 has long been 
suspected as a culprit whose inhibition plays a role in MSS.  In addition, MT-1 MMP (MMP-14) 
knockout mice suffer connective tissue disease due to inadequate collagen turnover14 and 
impaired endochondral ossification15 reminiscent of joint lesions in MSS.  We have therefore 
concentrated our efforts on potently inhibiting MMP-13 while sparing other MMPs to achieve 
joint safety, in particular  MMP-1 and MMP-14, which we refer to as the dual-sparing 
hypothesis.  MMP-13 selective α-carboxylic acids have been reported by Wyeth researchers.16-18  
Moderately selective pyrimidinetrione MMP-13 inhibitors have been reported that gave rise to 
fibroplasia in a 14-day rat study, but MMP-14 data was not reported.19 
 
We previously described the synthesis and MMP inhibitory activity of β-sulfone 
hydroxamates20-21 and aryl-linked isosteres22-23 that potently inhibit MMP-2 and MMP-13 but 
spare MMP-1, and discovered that α-sulfone hydroxamates including SC-276 are superior to the 
β-sulfones in both MMP-1 sparing enzyme profiles and ADME properties, and exhibit excellent 
oral antitumor efficacy in vivo.24  MMP-1 sparing α-sulfone hydroxamates have also been 
reported by the Wyeth group through modification of P1’ substituents,25, 26 and Wyeth 
researchers have also employed β-sulfones to attain potent and selective TACE inhibitors.27, 28  
Zhang et. al. of J&J have employed α-sulfone carboxylic acids as MMP-1 sparing gelatinase 
(MMP-2/9) inhibitors.29  Our work in exploring modifications in the P’ region toward further 
enhancing MMP-13 selectivity through interaction with the S1’ pocket has afforded a series of 
aryl piperidines and isonipecotamide derivatives that are highly selective for MMP-13 and 
sparing of both MMP-1 and MMP-14 as we report herein. 
 
Isonipecotamide sulfone hydroxamates 4 in the α-tetrahydropyran series were prepared as 
outlined in Scheme 1.  Carboxylic acid 124 was coupled with the hydroxamate-containing 
modified Wang resin of Floyd30 employing benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) as the coupling agent with N-methylmorpholine (NMM) in N-
methylpyrrolidinone (NMP) to give polymer-bound aryl fluoride 2.  Nucleophilic aromatic 
substitution with a 10-fold excess of ethyl isonipecotate in NMP, and subsequent hydrolysis of 
the ethyl ester gave resin-bound carboxylic acid 3.  The polymer-bound acid was activated with 
PyBOP and reacted with the requisite amine to give the corresponding polymer-bound amides, 
which were liberated from the resin with TFA to afford isonipecotamides 4. 
 
Scheme 1.  Synthesis of isonipecotamide sulfone hydroxamates in the α-tetrahydropyran series 
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Isonipecotamides 4 in the α-piperidine sulfone series were prepared by traditional solution-
phase methodologies as outlined in Scheme 2.  Ethyl isonipecotate N-tert-butylcarbamate 531 
was coupled with the requisite amine using 2-chloro-4,6-dimethoxy-1,3,5-trazine (CDMT) as a 
coupling reagent followed by deprotection with HCl to afford piperidine 6.  Nucleophilic 
aromatic displacement of aryl fluoride 724 gave the aryl piperidine sulfone 8.  Hydrolysis of the 
ethyl ester, coupling with THP-protected hydroxylamine using EDC and HOBT followed by 
acidic deprotection afforded the hydroxamates 4 as the α-piperidine hydrochloride salts.  
 
Scheme 2.  Synthesis of isonipecotamide sulfone hydroxamates in the α-piperidine series 
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The inhibitory potencies of α-tetrahydropyranyl and α-piperidine sulfone hydroxamates 4a-w 
versus MMP-2 and MMP-13 are summarized in Table 1 wherein the isonipecotic acid amide 
moiety was varied.  Also shown in Table 1 is a selectivity ratio derived from dividing the IC50 at 
MMP-2 by that of MMP-13.  Moderate potencies for MMP-13 were maintained, and single-digit 
nanomolar potency was attained for several analogs.  All compounds had IC50 values of >10,000 
nM for MMP-1 (not shown), thus selectivities for MMP-13 versus MMP-1 varied from >100X 
(4n) to >2000X.  Selectivity ratios versus MMP-2 were generally in a range of 50 to 500, and as 
high as 1659 for 4f.  Allyl and propargyl derivatives 4a and 4b were moderately potent for 
MMP-13 with selectivities versus MMP-2 of approximately 85X.  Selectivities rose for aralkyl 
substituted derivatives 4c, 4d and 4e to nearly 400X for 4e.  3,5-Dimethylpiperidine amide 4f 
(mixture of cis and trans isomers) distinguished itself as the most potent for MMP-13 (IC50 = 4.4 
nM) and the most selective versus MMP-2 as well (1659X).  The corresponding α-piperidine N-
methoxyethyl 4g analog was prepared to improve aqueous solubility and ADME properties 
relative to 4f (X = O).  Surprisingly the MMP-13 potency for 4g dropped to an IC50 of 50 nM, 
although α-piperidines were as potent as α-tetrahydropyrans in the broader-spectrum, MMP-1 
sparing series,24 while the potency for MMP-2 increased modestly to 1700 nM resulting in a 50-
fold drop in selectivity versus MMP-2.  cis-Dimethylmorpholine 4h was 4X less potent than 4f, 
suggesting that the trans isomer may be the more potent isomer in 4f.  Piperazine amides 4i-4n 
suffered a loss of potency for MMP-13, particularly with the introduction of a basic amine 
leading to the least potent analog 4n.  N-Aryl piperazine amides 4o-4w in general were more 
potent for MMP-13 with good selectivities versus MMP-2.  Fluoro analogs 4o and 4q were 
among the most potent analogs (IC50 = 6.7 nM and 6.0 nM, resp.), along with 4-acyl derivative 
4r.  The 2,4-dimethylphenyl analog 4s maintained decent potency for MMP-13 (IC50 = 12.2 nM) 
and was less potent at MMP-2 leading to a selectivity of 460X.  MMP-13 tolerated heterocyclic 
analogs 4t-4w with a nitrogen in the 2-position of 4t and 4u (IC50 = 10.7 and 6.4 nM, resp.) with 
good selectivities (330X and 300X, resp.), whereas a nitrogen in the 3- or 4-position led to a loss 
of some potency and selectivity (4v and 4w).  
 
Table 2 summarizes inhibitory potency for 2,3-dimethylphenylpiperidine amides 4x, 4y, and 
4z.  The α-tetrahydropyranyl (X = O) compound 4x distinguished itself as both the most potent 
and selective of the isonipecotic amides, with an IC50 for MMP-13 of 4.0 nM and selectivity of 
40X versus MMP-3, 1500X versus MMP-2, and >2500X versus MMPs-1, 8, 9, and 14.  
Unfortunately, this compound was below the detection level when dosed orally in rats.  The 
corresponding N-cyclopropyl and N-methoxyethyl piperidine analogs 4y and 4z were thus 
prepared, but the MMP-13 inhibitory potency for these compounds dropped 7X and 17X, 
respectively. 
 
Table 3 shows the MMP inhibitory and rat PK data for aniline amide 4aa, which had good 
potency for MMP-13 (IC50 = 9.0 nM) and very good selectivities versus both MMP-1 and MMP-
14 (>1100X).  However, exposure and half life in the rat were very poor after oral dosing, with a 
half life of less than one hour, and a BA of only 4%.  Isonipecotamide hydroxamates described 
herein have demonstrated double-digit to single-digit potency for MMP-13 combined with very 
good selectivity versus MMP-1 (110 to 2500) and versus MMP-2 ranging from 30X to 1,500X.  
Compound 4x exhibits >2,500X selectivity for MMP-13 versus both MMP-1 and MMP-14, 
hence we refer to this profile as dual-sparing (eg. MMP-13 potency while sparing both MMP-1 
and MMP-14).  Yet rat PK for 4aa was disappointing, but not surprising with a high molecular 
weight of 544 a.u.34  We therefore turned our attention to lower molecular weight species, while 
applying our learnings about P1´ manipulations toward optimizing MMP-13 selectivity and 
ultimately to MMP-1/14 dual-sparing profiles with lower MW and fewer reduce rotatable bonds 
as described in the subsequent publication.35 
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